Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

As research continues, Mounjaro may redefine medical weight loss strategies, but its ethical implications and long-term ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management.

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India following approval from the country's drug ...

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes ...

Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...